Hematologic MalignanciesNCT07285668
Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies
A study testing Allogeneic donor TCRαβ+/CD19+ cell-depleted peripheral blood mononuclear cells in people with Hematologic Malignancies, run by University of Wisconsin, Madison at 1 site in United States.
Trial summary
This study is being done to assess the safety and determine the maximum tolerable dose (MTD) of TCRαβ+/CD19+-depleted Donor Lymphocyte Infusion (αβT/B dep-DLI) after allogeneic stem cell transplant (allo-SCT) in highrisk patients with hematologic malignancies. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Hematologic Malignancies
- What is being tested?
- Allogeneic donor TCRαβ+/CD19+ cell-depleted peripheral blood mononuclear cells
- Type of treatment
- Injection or infusion, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 38 participants
- Where
- 1 siteUnited States
- Study dates
- 26 Feb 2026to Feb 2031
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with high-risk myeloid or lymphoid malignancies determined to be eligible to undergo allo-SCT including but not limited to the conditions listed below. These criteria apply at the disease diagnosis or any time prior to the cyto-reductive therapy given before the planned conditioning:
- Refractory acute myelogenous (AML) or lymphoid leukemia (ALL)
- Relapsed AML or ALL
- AML in European LeukemiaNet (ELN) high risk per cytogenetic and mutation
- Any patients with minimal residual disease (MRD+) disease by flow cytometry or with active disease (not in complete remission (CR)) prior to allo-SCT
- Myelodysplastic syndromes (MDS) with 5% or more blasts at initial diagnosis, or anytime during their treatment prior to allo-SCT.
Show all 20Show fewer
- Myelodysplastic syndrome (MDS) high risk or very high risk per Revised International Prognostic Scoring System (IPSS-R) or Molecular International Prognostic Scoring System (IPSS-M)
- Chronic myelogenous leukemia (CML) in chronic phase failed 3 or more treatments, in accelerated or blast phase
- High risk primary myelofibrosis (PMF) per Dynamic International Prognostic Scoring System (DIPSS)-plus or Mutation-enhanced International Prognostic Scoring System for Transplant-age Patients (MIPSS70+)
- PMF in accelerated or blast phase
- Recurrent or refractory malignant lymphoma or Hodgkin's disease with less than a partial response at transplant
- High risk chronic lymphocytic leukemia defined as no response or stable disease to the most recent treatment regimen
- Other high risk hematologic malignancies for which allo-SCT is deemed clinically necessary per PI and based on institutional standards
- The donor for the allo-SCT must be:
- Related AND
- Matched OR mismatched OR haploidentical at HLA-A, -B, -C, and -DRB1 by molecular methods
- ECOG performance score of 0-2
- Ability to understand and willingness to sign written informed consent document
- Willing to comply with all study procedures and be available for the duration of the study
- Individuals in sexual relationships that could result in pregnancy or impregnation of their partner must use an acceptable method of contraception§ from enrollment until 4 weeks after completing study treatment.
Who cannot join
- Poor organ function as follows (According to the pre-transplant workups results):
- Creatinine ≥ 2.0 mg/dL
- SGOT and SGPT ≥ 5 x ULN. Liver biopsy per clinician discretion.
- Bilirubin ≥ 3 x ULN (unless Gilbert's syndrome)
- DLCO < 50% corrected for hemoglobin
- Left ventricular ejection fraction or shortening fraction < 40%
Show all 9Show fewer
- NOTE: Exceptions to the above organ function exclusion criteria are allowable only with assent of the PI since the risks and benefits must be addressed for patients with potentially incurable hematologic malignancies. Such exceptions will be clearly documented in the subject's research record and will not be considered a deviation.
- Patients with uncontrolled intercurrent illness
- Patients with psychiatric illness/social situations that would limit compliance with study requirements
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
UW Carbone Cancer Center
Madison, Wisconsin, 53792
About this study
Official title: Phase I Study of Prophylactic TCRαβ+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies
This study is being done to assess the safety and determine the maximum tolerable dose (MTD) of TCRαβ+/CD19+-depleted Donor Lymphocyte Infusion (αβT/B dep-DLI) after allogeneic stem cell transplant (allo-SCT) in highrisk patients with hematologic malignancies.
Read the detailed description
Primary Objectives
- To assess safety of prophylactic TCRαβ+/CD19+ depleted donor lymphocyte infusion (αβT/B dep-DLI) after allogeneic stem cell transplant (allo-SCT) in high-risk patients with hematologic malignancies
- To determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) of αβT/B dep-DLI
Secondary Objectives
- To assess the feasibility of αβT/B dep-DLI
- To assess additional safety parameters after αβT/B dep-DLI
- To assess the efficacy of αβT/B dep-DLI
For the dose escalation phase: Maximum Tolerated Dose (MTD) and Maximum Administered Dose (MAD) is defined as the highest dose level where less than 2 of 6 participants experience a dose limiting toxicity (DLT).
Each dose level will be followed for DLTs until day 28 post donor lymphocyte infusion (DLI). Starting at dose level 1:
- If 0 of 3 participants experiences DLT, increase to next dose level for next 3 participants.
- If 1 of 3 participants experience DLT, enroll 3 participants at same dose level.
- If no additional DLTs (1 of 6), move on to next dose level.
- If 2 of 6 participants experience DLT, enroll 3 participants into lower dose level.
- If 0 or 1 participants experience DLT at lower level, this will be the MTD.
Once the MTD or MAD is determined, an expansion cohort will be enrolled into that dose level.
All participants will be followed for 2 years after DLI.
- Conditions
- Hematologic Malignancies
- Being tested
- Allogeneic donor TCRαβ+/CD19+ cell-depleted peripheral blood mononuclear cells
- Keywords
- allogeneic donor, Lymphocyte Infusion
- Medical subject headings
- Hematologic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Allogeneic donor TCRαβ+/CD19+ cell-depleted peripheral blood mononuclear cellsDevice
Single intravenous dose of allogeneic donor TCRαβ+/CD19+ cell-depleted peripheral blood mononuclear cells (i.e., αβT/B dep-DLI), where the dose is based on the natural killer (NK) cell (CD3-CD56+) content in the DLI product. Each participant will receive one of four DLI doses depending upon cohort to which the participant is enrolled.
| Study group | Role | What they receive |
|---|---|---|
| Dose Escalation Cohort Level 1 | Experimental | 1 x 10^6 CD3-CD56+/kg Receives: Device: Allogeneic donor TCRαβ+/CD19+ cell-depleted peripheral blood mononuclear cells |
| Dose Escalation Cohort Level 2 | Experimental | 2 X 10^6 CD3-CD56+/kg Receives: Device: Allogeneic donor TCRαβ+/CD19+ cell-depleted peripheral blood mononuclear cells |
| Dose Escalation Cohort Level 3 | Experimental | 5 X 10^6 CD3-CD56+/kg Receives: Device: Allogeneic donor TCRαβ+/CD19+ cell-depleted peripheral blood mononuclear cells |
| Dose Escalation Cohort Level -1 | Experimental | 0.5 x 10^6 CD3-CD56+/kg
Dose to be used only if Dose Level 1 is not tolerated. Receives: Device: Allogeneic donor TCRαβ+/CD19+ cell-depleted peripheral blood mononuclear cells |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of Adverse Events (AEs) from DLI to day 28 post-DLI
To assess safety of prophylactic TCRαβ+/CD19+ depleted donor lymphocyte infusion (αβT/B dep-DLI) after allogeneic stem cell transplant (allo-SCT) in high-risk patients with hematologic malignancies, incidence of AEs will be reported.
Measured: up to day 28 post-DLI (approximately day 63 on study)
Maximum Tolerated Dose or Maximum Administered Dose
MTD/MAD defined as the highest dose level at which less than 2 of 6 participants experience a DLT.
Measured: up to day 28 post-DLI (approximately day 63 on study)
Secondary outcomes (12)
Incidence of grade II-IV acute Graft-versus-Host Disease (aGVHD) after αβT/B dep-DLI
To assess additional safety parameters after allo-SCT in high-risk patients with hematologic malignancies, Incidence of grade II-IV aGVHD after αβT/B dep-DLI will be reported.
Measured: up to day 28 post-DLI (approximately day 63 on study)
Cumulative incidence of severe grade III-IV aGVHD after αβT/B dep-DLI
To assess additional safety parameters after allo-SCT in high-risk patients with hematologic malignancies, cumulative incidence of severe grade III-IV aGVHD after αβT/B dep-DLI will be reported.
Measured: up to day 28 post-DLI (approximately day 63 on study)
Chronic Graft-versus-Host Disease (GVHD) incidence after αβT/B dep-DLI
To assess additional safety parameters after allo-SCT in high-risk patients with hematologic malignancies, chronic GVHD incidence after αβT/B dep-DLI will be reported.
Measured: up to day 28 post-DLI (approximately day 63 on study)
Efficacy assessed by 1 year Progression Free Survival (PFS)
To assess the efficacy of prophylactic αβT/B dep-DLI after allo-SCT in high-risk patients with hematologic malignancies, 1 year PFS will be reported.
Measured: up to 1 year
Efficacy Assessed by Non-Relapse Mortality
To assess the efficacy of prophylactic αβT/B dep-DLI after allo-SCT in high-risk patients with hematologic malignancies, non-relapse mortality will be reported.
Measured: up to 2 years
Efficacy Assessed by Overall Survival
To assess the efficacy of prophylactic αβT/B dep-DLI after allo-SCT in high-risk patients with hematologic malignancies, overall survival will be reported.
Measured: up to 2 years
Efficacy Assessed by Incidence of Cytomegalovirus (CMV) Reactivation
To assess the efficacy of prophylactic αβT/B dep-DLI after allo-SCT in high-risk patients with hematologic malignancies, incidence of CMV Reactivation will be reported.
Measured: up to 2 years
Efficacy Assessed by Incidence of Fungal Infection
To assess the efficacy of prophylactic αβT/B dep-DLI after allo-SCT in high-risk patients with hematologic malignancies, incidence of fungal infections will be reported.
Measured: up to 2 years
Efficacy Assessed by Incidence of Full Chimerism (CD3 compartment)
To assess the efficacy of prophylactic αβT/B dep-DLI after allo-SCT in high-risk patients with hematologic malignancies, incidence of full chimerism will be reported.
Measured: up to 2 years
Efficacy Assessed by Immunoglobulin Levels
To assess the efficacy of prophylactic αβT/B dep-DLI after allo-SCT in high-risk patients with hematologic malignancies, quantitative immunoglobulin levels will be reported.
Measured: up to 2 years
Efficacy Assessed by Lymphocyte Panel Analysis
To assess the efficacy of prophylactic αβT/B dep-DLI after allo-SCT in high-risk patients with hematologic malignancies, lymphocyte subset panel analysis will be conducted and reported.
Measured: up to 2 years
Feasibility assessed by percentage of enrolled participants who are able to receive depleted DLI
To assess the feasibility of prophylactic αβT/B dep-DLI after allo-SCT in high-risk patients with hematologic malignancies, the percentage of enrolled participants who are able to receive depleted DLI will be reported.
Measured: up to approximately 35 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Dec 2025
- Study start26 Feb 2026
- Primary completionFeb 2029 (estimated)
- Study completionFeb 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hematologic MalignanciesStudies of the same condition, open and under way.
- More trials run by University of Wisconsin, MadisonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Model description
- This is a single-center, phase I 3x3 dose-escalation study with expansion cohort, open label, non-randomized, non-placebo controlled, single-group assignment study.
- Masking
- None (open label)
- Enrolment
- 38 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Wisconsin, Madison
- Sponsor type
- University, hospital or other
- Collaborators
- Miltenyi Biomedicine GmbH
- Responsible party
- Sponsor
- Investigators
- Jacques Galipeau, MD, FRCP(C), Study director, UW School of Medicine and Public HealthHongtao Liu, MD, PhD, Principal investigator, UW Carbone Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07285668
- Sponsor's protocol ID
- 2025-1405
- Other IDs
- UW25034, Protocol Version 5/5/26, SMPH/MEDICINE/HEM-ONC
- Status last verified
- Sep 2026
- First submitted
- 9 Dec 2025
- Last updated
- 14 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- Yes: The Principal Investigator, Sponsor and funding institutions (if applicable) will ensure that all mechanisms used to share data include proper plans and safeguards to protect the rights and privacy of participants who participate in this research. Data from this study may be requested from other researchers 5 years after the completion of the primary endpoint by contacting the Principal Investigator, Dr. Hongtao Liu.
Study at a glance
From the registry record, last updated by the sponsor on 14 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase I Study of Prophylactic TCRαβ+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies
- ClinicalTrials.gov ID
- NCT07285668
- Acronym / sponsor ID
- 2025-1405
- Conditions
- Hematologic Malignancies
- Keywords
- allogeneic donor, Lymphocyte Infusion
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 38 participants (estimated)
- Lead sponsor
- University of Wisconsin, MadisonUniversity, hospital or other
- Collaborators
- Miltenyi Biomedicine GmbH
- Study start
- 26 Feb 2026 (actual)
- Primary completion
- Feb 2029 (estimated)
- Study completion
- Feb 2031 (estimated)
- First posted
- 16 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is being done to assess the safety and determine the maximum tolerable dose (MTD) of TCRαβ+/CD19+-depleted Donor Lymphocyte Infusion (αβT/B dep-DLI) after allogeneic stem cell transplant (allo-SCT) in highrisk patients with hematologic malignancies.
Detailed description
Primary Objectives
- To assess safety of prophylactic TCRαβ+/CD19+ depleted donor lymphocyte infusion (αβT/B dep-DLI) after allogeneic stem cell transplant (allo-SCT) in high-risk patients with hematologic malignancies
- To determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) of αβT/B dep-DLI
Secondary Objectives
- To assess the feasibility of αβT/B dep-DLI
- To assess additional safety parameters after αβT/B dep-DLI
- To assess the efficacy of αβT/B dep-DLI
For the dose escalation phase: Maximum Tolerated Dose (MTD) and Maximum Administered Dose (MAD) is defined as the highest dose level where less than 2 of 6 participants experience a dose limiting toxicity (DLT).
Each dose level will be followed for DLTs until day 28 post donor lymphocyte infusion (DLI). Starting at dose level 1:
- If 0 of 3 participants experiences DLT, increase to next dose level for next 3 participants.
- If 1 of 3 participants experience DLT, enroll 3 participants at same dose level.
- If no additional DLTs (1 of 6), move on to next dose level.
- If 2 of 6 participants experience DLT, enroll 3 participants into lower dose level.
- If 0 or 1 participants experience DLT at lower level, this will be the MTD.
Once the MTD or MAD is determined, an expansion cohort will be enrolled into that dose level.
All participants will be followed for 2 years after DLI.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 4
- Model description
- This is a single-center, phase I 3x3 dose-escalation study with expansion cohort, open label, non-randomized, non-placebo controlled, single-group assignment study.
| Arm | Type | Receives |
|---|---|---|
| Dose Escalation Cohort Level 1 | Experimental | Device: Allogeneic donor TCRαβ+/CD19+ cell-depleted peripheral blood mononuclear cells1 x 10^6 CD3-CD56+/kg |
| Dose Escalation Cohort Level 2 | Experimental | Device: Allogeneic donor TCRαβ+/CD19+ cell-depleted peripheral blood mononuclear cells2 X 10^6 CD3-CD56+/kg |
| Dose Escalation Cohort Level 3 | Experimental | Device: Allogeneic donor TCRαβ+/CD19+ cell-depleted peripheral blood mononuclear cells5 X 10^6 CD3-CD56+/kg |
| Dose Escalation Cohort Level -1 | Experimental | Device: Allogeneic donor TCRαβ+/CD19+ cell-depleted peripheral blood mononuclear cells0.5 x 10^6 CD3-CD56+/kg Dose to be used only if Dose Level 1 is not tolerated. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (20 listed)
- Patients with high-risk myeloid or lymphoid malignancies determined to be eligible to undergo allo-SCT including but not limited to the conditions listed below. These criteria apply at the disease diagnosis or any time prior to the cyto-reductive therapy given before the planned conditioning:
- The donor for the allo-SCT must be:
- ECOG performance score of 0-2
- Ability to understand and willingness to sign written informed consent document
- Willing to comply with all study procedures and be available for the duration of the study
Key exclusion criteria (9 listed)
- Poor organ function as follows (According to the pre-transplant workups results):
- Creatinine ≥ 2.0 mg/dL
- SGOT and SGPT ≥ 5 x ULN. Liver biopsy per clinician discretion.
- Bilirubin ≥ 3 x ULN (unless Gilbert's syndrome)
- DLCO < 50% corrected for hemoglobin
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Allogeneic donor TCRαβ+/CD19+ cell-depleted peripheral blood mononuclear cellsSingle intravenous dose of allogeneic donor TCRαβ+/CD19+ cell-depleted peripheral blood mononuclear cells (i.e., αβT/B dep-DLI), where the dose is based on the natural killer (NK) cell (CD3-CD56+) content in the DLI product. Each participant will receive one of four DLI doses depending upon cohort to which the participant is enrolled. | Device | Dose Escalation Cohort Level -1, Dose Escalation Cohort Level 1, Dose Escalation Cohort Level 2, Dose Escalation Cohort Level 3 |
Primary outcome
Incidence of Adverse Events (AEs) from DLI to day 28 post-DLI
Time frame: up to day 28 post-DLI (approximately day 63 on study)
To assess safety of prophylactic TCRαβ+/CD19+ depleted donor lymphocyte infusion (αβT/B dep-DLI) after allogeneic stem cell transplant (allo-SCT) in high-risk patients with hematologic malignancies, incidence of AEs will be reported.
Maximum Tolerated Dose or Maximum Administered Dose
Time frame: up to day 28 post-DLI (approximately day 63 on study)
MTD/MAD defined as the highest dose level at which less than 2 of 6 participants experience a DLT.
12 secondary outcomes
Incidence of grade II-IV acute Graft-versus-Host Disease (aGVHD) after αβT/B dep-DLI
Time frame: up to day 28 post-DLI (approximately day 63 on study)
Cumulative incidence of severe grade III-IV aGVHD after αβT/B dep-DLI
Time frame: up to day 28 post-DLI (approximately day 63 on study)
Chronic Graft-versus-Host Disease (GVHD) incidence after αβT/B dep-DLI
Time frame: up to day 28 post-DLI (approximately day 63 on study)
Efficacy assessed by 1 year Progression Free Survival (PFS)
Time frame: up to 1 year
Efficacy Assessed by Non-Relapse Mortality
Time frame: up to 2 years
Efficacy Assessed by Overall Survival
Time frame: up to 2 years
Efficacy Assessed by Incidence of Cytomegalovirus (CMV) Reactivation
Time frame: up to 2 years
Efficacy Assessed by Incidence of Fungal Infection
Time frame: up to 2 years
Efficacy Assessed by Incidence of Full Chimerism (CD3 compartment)
Time frame: up to 2 years
Efficacy Assessed by Immunoglobulin Levels
Time frame: up to 2 years
Efficacy Assessed by Lymphocyte Panel Analysis
Time frame: up to 2 years
Feasibility assessed by percentage of enrolled participants who are able to receive depleted DLI
Time frame: up to approximately 35 days
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Sep 2026.
- Stem Cell and Regenerative Medicine CenterLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. The Principal Investigator, Sponsor and funding institutions (if applicable) will ensure that all mechanisms used to share data include proper plans and safeguards to protect the rights and privacy of participants who participate in this research. Data from this study may be requested from other researchers 5 years after the completion of the primary endpoint by contacting the Principal Investigator, Dr. Hongtao Liu.
Related trials for Hematologic Malignancies
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Not yet recruitingPhase 2
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma (RRMM)
RecruitingPhase 2
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
Active, not recruitingPhase 3
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
Multiple Myeloma
Active, not recruitingPhase 1/2
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Multiple Myeloma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jacques Galipeau, MD, FRCP(C) study director
UW School of Medicine and Public Health
Hongtao Liu, MD, PhD principal investigator
UW Carbone Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Allogeneic donor TCRαβ+/CD19+ cell-depleted peripheral blood mononuclear cells in people with Hematologic Malignancies, run by University of Wisconsin, Madison at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 20 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 14 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Cancer Connect (800-622-8922, clinicaltrials@cancer.wisc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of Adverse Events (AEs) from DLI to day 28 post-DLI (time frame: up to day 28 post-DLI (approximately day 63 on study)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Sep 2026.